Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 17/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 15/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.38 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.38 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.34 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8172614 | 0.85 | ITGAV (0.38) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL12807108 | 0.83 | KCNH2 (0.42) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL26538782 | 0.81 | ITGB3 (0.39) | ITGAVITGB3ITGB1ITGA5PDE10A | |
| SCHEMBL8325969 | 0.81 | ITGAV (0.40) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL24440037 | 0.79 | ITGAV (0.39) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL2494472 | 0.79 | ITGAV (0.41) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL26457526 | 0.78 | ALDH1A1 (0.40) | ITGAVITGB3ITGB1ITGA5PDE10A | |
| SCHEMBL6106216 | 0.76 | ITGB3 (0.52) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL12807123 | 0.76 | KCNH2 (0.41) | ITGAVITGB3ITGB1ITGB6ITGA2B | |
| SCHEMBL14476045 | 0.75 | GRM5 (0.39) | ITGAVITGB3ITGB1ITGA5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20080255183-A1 | N-[HETEROARYLCARBONYL]-3-THIENYL-L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080182842-A1 | L-alanine derivatives as a5beta1 antagonists | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255183-A1 | N-[HETEROARYLCARBONYL]-3-THIENYL-L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ITGA2B, ITGB1, ITGB5 | ITGAV 9/4885ITGB3 5/4885ITGB1 2/4885 |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | ITGAV 17/4885ITGB3 6/4885ITGB1 2/4885 |
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ITGA2B, ITGB1, ITGAL | ITGAV 9/4885ITGB3 12/4885ITGB1 2/4885 |
| US-20080182842-A1 | L-alanine derivatives as a5beta1 antagonists | ITGB1, ITGA2B, ITGB5 | ITGAV 7/4885ITGB3 10/4885ITGB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.